# iOnctura: Research, Geneva, Switzerland

> iOnctura: iOnctura is a clinical-stage biopharmaceutical company focused on developing therapies for neglected and hard-to-treat cancers.

Source: https://millionrounds.com/startup/ionctura (Millionrounds; every figure on the page links to its filing or article)

Switzerland · [Research startup](https://millionrounds.com/companies)

# iOnctura

iOnctura is a clinical-stage biopharmaceutical company focused on developing therapies for neglected and hard-to-treat cancers.

Funding reported Last round: Series B

Research Geneva, Switzerland

Company summary

- **Founded:** 2017 9 years old
- **Team:** 34 11 to 50 people
- **Funding reported:** 127.7M as listed, currency not stated
- **Last round:** Series B Jun 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for iOnctura has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About iOnctura

iOnctura is a clinical-stage biopharmaceutical company focused on developing therapies for neglected and hard-to-treat cancers.

Founded in June 2017 as a spin-out from Merck Ventures, the company is headquartered in Geneva, Switzerland, with its operational parent located in Amsterdam, The Netherlands. iOnctura aims to extend patient healthspan by targeting cancers that face challenges from stroma and immune-mediated resistance. The company specializes in precision oral small molecules designed to be less toxic while effectively inhibiting tumor growth. iOnctura's pipeline includes clinical-stage candidates such as Roginolisib, the first allosteric modulator of PI3Kδ, and Cambritaxestat, the only autotaxin inhibitor in clinical development for cancer treatment. Their innovative approach emphasizes low-disruption therapies and combination therapy development, aiming to improve patient quality of life and treatment outcomes.

## What company datasets say iOnctura raised

Funding, as reported

Reported in all **127.7M** in the source's currency

Rounds **9**

Last round **Series B**

Last round size **88M**

Last round date **Jun 2024**

Investors listed **11**

## On 3 portfolio pages

Investors who name them

- [3B Future Health Fund I & II](https://millionrounds.com/fund/3b-future-health-fund-i-and-ii)
- [Inkef](https://millionrounds.com/fund/inkef-capital)
- [XGEN Venture](https://millionrounds.com/fund/xgen-venture)

Each firm lists iOnctura on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

tgf-beta inhibitors health care biotechnology research allosteric modulation manufacturing medical research tumor resistance autotaxin inhibitors combination immunotherapy hospital & health care precision oncology immune escape medical health biotechnology mechanical or industrial engineering

Built with from their website

Google Tag Manager LiteSpeed WordPress.org Viewport Meta EWWW Image Optimizer Amazon S3 Webflow Hosting Apple Business Manager KnowBe4 Priority Hints

+8 more

CAPTCHA Google Font API Microsoft Exchange MySQL PrimeNG Unpkg Microsoft 365 Apps & Services Mobile Friendly

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** Geneva
- **Revenue:** 780k a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/ionctura)

## Research in Switzerland

Startups like it

- [**Nouscom** Basel · founded 2015 *Raised*](https://millionrounds.com/company/nouscom)
- [**Hedera Dx** Epalinges · founded 2021 *Raised*](https://millionrounds.com/company/hedera-dx)
- [**Bio Protocol** Zug *Raised*](https://millionrounds.com/company/bio-protocol)
- [**InVirtuoLabs** Lugano · founded 2024 *Raised*](https://millionrounds.com/company/invirtuolabs)
- [**NEMIS Technologies** Waedenswil · founded 2018 *Raised*](https://millionrounds.com/company/nemis-technologies)
- [**Windward Bio** Basel](https://millionrounds.com/startup/windward-bio)
- [**Bright Peak Therapeutics** Basel · founded 2017](https://millionrounds.com/startup/bright-peak-therapeutics)
- [**Numab Therapeutics AG** Horgen · founded 2011](https://millionrounds.com/startup/numab-therapeutics-ag)

## Is this your company?

Add your raise, your deck and your story, and put iOnctura in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)